Pourquoi DOCTOLIB vaut elle moins cher au moment même où son modèle paraît plus solide ?
法国医疗预约平台Doctolib近期在二级市场的股权交易中，其隐含估值已降至36亿欧元，远低于四年前新冠疫情高峰期58亿欧元的估值峰值。这一变化引人关注，因为公司不久前才宣布实现盈利，商业模式看似更加稳固。
据彭博社报道，此次估值下调源于一次二级市场的股份转让。尽管Doctolib在2023年首次实现全年盈利，并持续扩大在法国和德国市场的领先地位，其估值却较2021年的高点大幅缩水近40%。
市场分析认为，估值下降主要反映了宏观投资环境的转变。四年前，在零利率和科技股投资热潮的推动下，高增长科技企业普遍获得极高溢价。如今，随着利率上升和投资者转向关注盈利能力与现金流，整个科技行业的估值体系已发生根本性调整。
Doctolib的案例凸显了当前私募市场的新逻辑：即使企业基本面向好并实现盈利，估值也可能因融资环境收紧而承压。这标志着欧洲科技行业正从追求增长转向更注重可持续的商业模式。
French healthtech leader Doctolib has reportedly accepted a significant down-round in its valuation, even as its business model appears more robust. According to Bloomberg, a recent secondary share sale implies a company valuation of approximately €3.6 billion. This marks a sharp decline from its peak valuation of €5.8 billion reached four years ago during the post-Covid investment euphoria.
This devaluation occurs against a paradoxical backdrop: Doctolib recently announced it has achieved profitability, a key milestone suggesting a stronger and more sustainable operational foundation. The divergence highlights a broader market correction where investor sentiment and valuation multiples have cooled dramatically since 2021, despite improvements in company fundamentals. The reset reflects a new era of investor scrutiny focused on proven profitability over growth-at-all-costs narratives, even for established market leaders.
Quelques mois après avoir annoncé l’atteinte de la rentabilité, Doctolib aurait, selon les informations de Bloomberg, accepté une valorisation implicite de 3,6 milliards d’euros à l’occasion d’une cession de titres sur le marché secondaire. Quatre ans plus tôt, au pic de l’euphorie post-Covid, l’entreprise était valorisée 5,8 milliards d’euros. Entre ces deux points, la trajectoire …
L’article Pourquoi DOCTOLIB vaut elle moins cher au moment même où son modèle paraît plus solide ? est apparu en premier sur FW.MEDIA.
Doctolib's secondary share sale implies a €3.6B valuation, down from its €5.8B post-Covid peak, despite recently announcing profitability, reflecting a broader market correction for tech growth stocks.
Doctolib — French online medical appointment booking and practice management software provider.
Monitor — This valuation shift is a key indicator of European healthtech and late-stage private market sentiment.